Multiple myeloma, Lancet, vol.374, pp.324-363, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130206
Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data, The Oncologist, vol.18, pp.37-45, 2013. ,
Monoclonal antibodybased therapy as a new treatment strategy in multiple myeloma, Expert Opin Biol Ther, vol.26, pp.199-213, 2012. ,
,
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, Haematologica, vol.93, pp.431-439, 2008. ,
Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma, Am J Clin Pathol, vol.132, pp.728-760, 2009. ,
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br J Haematol, vol.149, pp.334-51, 2010. ,
Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma, Am J Clin Pathol, vol.127, pp.176-81, 2007. ,
,
,
, Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases, Leuk Res, vol.38, pp.371-377, 2014.
,
CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, pp.4194-4201, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130595
CD200: a putative therapeutic target in cancer, Biochem Biophys Res Commun, vol.366, pp.117-139, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00195258
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma, Am J Clin Pathol, vol.138, pp.867-76, 2012. ,
,
Regulation of multiple myeloma survival and progression by CD1d, Blood, vol.113, pp.2498-507, 2009. ,
,
, antibodies promote phagocytosis and inhibit the growth of human myeloma cells
, Leukemia, vol.26, pp.2538-2583, 2012.
,
, Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma
, Br J Haematol, vol.138, pp.756-60, 2007.
High expression of CD59 and CD55 on benign and malignant plasma cells, Leuk Lymphoma, vol.47, pp.919-940, 2006. ,
Age-associated changes in counts and detailed characterization of 5 circulating normal CD138-and CD138+ plasma cells, Haematologica, vol.95, pp.1016-1020, 2010. ,
,
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?, 10 Oncotarget, vol.3, pp.1335-1347, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00802665
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014. ,
, , 2008.
, Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy, J. Clin. Oncol, vol.26, pp.2737-2744
, , 2008.
, Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, pp.4017-4023
, , 2012.
, Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials, Am. J. Pathol, vol.181, pp.1870-1878
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapse multiple myeloma, Haematologica, 2014. ,
Rapid cell population identification in flow cytometry data, Cytom. Part J. Int. Soc. Anal. Cytol, vol.79, pp.6-13, 2011. ,
Critical assessment of automated flow cytometry data analysis techniques, Nat. Methods, vol.10, pp.228-238, 2013. ,
Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation, Bone Marrow Transplant, vol.51, pp.529-535, 2016. ,
Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma, Am. J. Clin. Pathol, vol.137, pp.93-100, 2012. ,
High expression of CD59 and CD55 on benign and malignant plasma cells, Leuk. Lymphoma, vol.47, pp.919-921, 2006. ,
, , 1972.
, Combination chemotherapy for multiple myeloma, Cancer, vol.30, pp.382-389
The Ins and Outs of Lipid Flip-Flop, Acc. Chem. Res, 2016. ,
High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma, Br. J. Haematol, vol.107, pp.121-131, 1999. ,
Gene expression profiling (GEP) of cd 138-purified plasma cells (pc) in previously treated multiple myeloma (PTMM): Validating prognostic models developed in newly diagnosed MM (NDMM), J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.27, p.8598, 2009. ,
Assessment of different permeabilization methods of minimizing damage to the adherent cells for detection of intracellular RNA by flow cytometry, 2014. ,
, Avicenna J. Med. Biotechnol, vol.6, pp.38-46
, , 2014.
, Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma, Eur. J. Haematol, vol.93, pp.41-47
Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting, Cytometry B Clin. Cytom, vol.90, pp.31-39, 2016. ,
,
Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01300806
, Trial. Blood, vol.126, pp.191-191
CD24: A Rheostat That Modulates Cell Surface Receptor Signaling of Diverse Receptors, Front. Cell Dev. Biol, vol.4, 2016. ,
Mécanisme d'adhérence des leucocytes aux fibres synthétiques. Application à la filtration sanguine. phdthesis, 2001. ,
A Survey of Flow Cytometry Data Analysis Methods, Adv. Bioinforma, 2009. ,
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy, Haematologica, vol.91, pp.1234-1240, 2006. ,
Chapter 6 -Bone marrow biopsy, pp.115-130, 2006. ,
Lenalidomide and dexamethasone in transplantineligible patients with myeloma, N. Engl. J. Med, vol.371, pp.906-917, 2014. ,
Clustering gene expression patterns, J. Comput. Biol. J. Comput. Mol. Cell Biol, vol.6, pp.281-297, 1999. ,
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing, J. R. Stat. Soc. Ser. B Methodol, vol.57, pp.289-300, 1995. ,
, , 1991.
, Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease, Blood, vol.78, pp.3021-3029
CD84 is a survival receptor for CLL cells, Oncogene, vol.33, pp.1006-1016, 2014. ,
Hematopoietic stem cell transplantation for multiple myeloma beyond, Blood, vol.115, pp.3655-3663, 2010. ,
Statistical methods for assessing agreement between two methods of clinical measurement, Lancet Lond. Engl, vol.1, pp.307-310, 1986. ,
Artificial neural networks for pattern recognition, Machine Learning Methods for Ecological Applications, pp.37-87, 1999. ,
,
The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint, Br. J. Haematol, vol.126, pp.355-363, 2004. ,
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat. Commun, vol.5, p.2997, 2014. ,
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival, Blood Cancer J, vol.6, p.511, 2016. ,
, Classification and Regression Trees, 1984.
Impact of interferon-? on hematopoiesis, Blood, vol.124, pp.2479-2486, 2014. ,
, , 2007.
Plasma cells in multiple myeloma express a natural killer cell-associated antigen, pp.56-57, 1990. ,
, Leu-19), Blood, vol.76, pp.377-382
High throughput methods to characterize protein permeation and release, Int. J. Pharm, vol.350, pp.272-278, 2008. ,
Age-associated changes in counts and detailed characterization of circulating normal CD138-and CD138+ plasma cells, Haematologica, vol.95, pp.1016-1020, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00456476
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma, Oncotarget, vol.3, pp.1335-1347, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00802665
, , 2004.
Low-risk identification in multiple myeloma using a new 14-gene model, Eur. J. Haematol, vol.89, pp.28-36, 2012. ,
,
, Erythrocyte lysis in isotonic solution of ammonium chloride: theoretical modeling and experimental verification, J. Theor. Biol, vol.251, pp.93-107
Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int. J. Hematol, vol.97, p.313, 2013. ,
The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts, Blood, vol.92, pp.3025-3034, 1998. ,
Role of white blood cells in filtration of blood cell suspensions, Biorheology, vol.20, pp.11-27, 1983. ,
, , 2012.
, Characterization of potential CD138 negative myeloma "stem cells, Haematologica, vol.97, pp.18-20
Novel human CD4+ T lymphocyte subpopulations defined by CD300a/c molecule expression, J. Leukoc. Biol, vol.82, pp.1126-1135, 2007. ,
Biochemical characterization of complex formation by human erythrocyte spectrin, Biochemistry (Mosc.), vol.23, pp.6091-6098, 1984. ,
, , 1964.
Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood, PLoS ONE, vol.8, 2013. ,
Filtration parameters influencing circulating tumor cell enrichment from whole blood, PloS One, vol.8, 2013. ,
, , 2012.
, Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness, Ann. Oncol, vol.23, pp.2356-2362
An Antibody-based Multifaceted Approach Targeting the Human Transferrin Receptor for the Treatment of B-cell Malignancies, J. Immunother. Hagerstown Md, vol.34, pp.500-508, 1997. ,
Transferrin receptors and the targeted delivery of therapeutic agents against cancer, Biochim. Biophys. Acta, vol.1820, pp.291-317, 2012. ,
Traitement du myélome multiple, Médecine Thérapeutique, vol.13, pp.437-449, 2007. ,
,
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome, J. Clin. Oncol, vol.26, pp.4798-4805, 2008. ,
Analyzing multivariate flow cytometric data in aquatic sciences, Cytometry, vol.13, pp.291-298, 1992. ,
Exploring the metabolic and genetic control of gene expression on a genomic scale, Science, vol.278, pp.680-686, 1997. ,
ELOQUENT-1: A phase III, randomized, openlabel trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006), J. Clin. Oncol, vol.30, 2012. ,
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.1319-1331, 2016. ,
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma, Expert Opin. Biol. Ther, pp.1-18, 2014. ,
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes, Leukemia, vol.26, pp.1908-1975, 2012. ,
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma, Leukemia, vol.26, pp.199-213, 2012. ,
CD138 expression in plasma cells is volatile and time-lag dependent, Egypt. J. Haematol, vol.39, pp.258-259, 2014. ,
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.36, pp.842-854, 1975. ,
,
International uniform response criteria for multiple myeloma, Leukemia, vol.20, pp.1467-1473, 2006. ,
Cluster analysis and display of genome-wide expression patterns, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.14863-14868, 1998. ,
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, Haematologica, vol.99, pp.232-242, 2014. ,
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia, Blood, vol.120, pp.5173-5180, 2012. ,
Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma, Oncotarget, vol.7, pp.23128-23140, 2016. ,
Merging mixture components for cell population identification in flow cytometry, Adv. Bioinforma, p.247646, 2009. ,
A Simple Method of Removing Leucocytes from Blood, Br. J. Exp. Pathol, vol.7, pp.281-286, 1926. ,
,
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma, Cytometry B Clin, 2016. ,
, , vol.90, pp.61-72
,
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma, Cytometry B Clin, 2016. ,
, , vol.90, pp.61-72
,
Genetics and Cytogenetics of Multiple Myeloma, Cancer Res, vol.64, pp.1546-1558, 2004. ,
,
Robust isolation of malignant plasma cells in multiple myeloma, 2014. ,
Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients, Int. J. Cancer, vol.112, pp.884-889, 2004. ,
flowPeaks: a fast unsupervised clustering for flow cytometry data via K-means and density peak finding, Bioinforma. Oxf. Engl, vol.28, pp.2052-2058, 2012. ,
The Chromatin Signature of Pluripotency: Establishment and Maintenance, Curr. Stem Cell Rep, vol.2, pp.255-262, 2016. ,
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma, Leuk. Lymphoma, vol.56, pp.602-607, 2015. ,
,
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma, Leukemia, vol.28, pp.2060-2065, 2014. ,
Lipids of human leukocytes: relation to cell type, J. Lipid Res, vol.8, pp.321-327, 1967. ,
Glycophorin in lipid bilayers, Proc. Natl. Acad. Sci. U. S. A, vol.71, pp.4653-4657, 1974. ,
Plasma cell labeling index, Methods Mol. Med, vol.113, pp.25-35, 2005. ,
International Staging System for Multiple Myeloma, J. Clin. Oncol, vol.23, pp.3412-3420, 2005. ,
, , 2009.
flowCore: a Bioconductor package for high throughput flow cytometry, BMC Bioinformatics, vol.10, p.106, 2009. ,
URL : https://hal.archives-ouvertes.fr/inria-00426746
From Laboratory to Clinic : The Story of CAM PA TH-1, Methods Mol. Med, vol.40, pp.243-266, 2000. ,
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, vol.21, issue.5, pp.155-157, 2010. ,
Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques, Am. J. Clin. Pathol, vol.136, pp.712-720, 2011. ,
Investigating the functional role of CD2BP2 in T cells, Int. Immunol, vol.19, pp.1313-1318, 2007. ,
Molecular mechanisms of novel therapeutic approaches for multiple myeloma, Nat. Rev. Cancer, vol.2, pp.927-937, 2002. ,
Apoptotic signaling by c-MYC, Oncogene, vol.27, pp.6462-6472, 2008. ,
A Simple Sequentially Rejective Multiple Test Procedure. Scand, J. Stat, vol.6, pp.65-70, 1979. ,
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, pp.87-95, 2011. ,
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma, Haematologica, vol.96, pp.87-95, 2011. ,
Robust estimators for expression analysis, Bioinforma. Oxf. Engl, vol.18, pp.1585-1592, 2002. ,
CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity, Cell Death Dis, vol.3, p.425, 2012. ,
Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma, Clin. Lymphoma Myeloma Leuk, vol.16, pp.59-64, 2016. ,
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma, Br. J. Haematol, vol.127, pp.165-172, 2004. ,
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, vol.94, pp.701-712, 1999. ,
URL : https://hal.archives-ouvertes.fr/hal-01595831
Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells, 2012. ,
, Korean J. Hematol, vol.47, pp.260-266
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, Br. J. Haematol, vol.100, pp.637-646, 1998. ,
An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization, Blood, vol.114, pp.5173-5181, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00446133
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies, Blood Cancer J, vol.2, p.89, 2012. ,
CD19 and CD32b Differentially Regulate Human B Cell Responsiveness, J. Immunol. Author Choice, vol.192, pp.1480-1490, 2014. ,
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica, vol.97, pp.622-630, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00727008
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy, Oncotarget, vol.5, pp.2487-2498, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01006634
, , 2015.
, GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells, PLoS Comput. Biol, vol.11, p.1004077
Evaluation of the Revised International Staging System (R-ISS) in an independent cohort of unselected patients with multiple myeloma, Haematologica, 2016. ,
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells, Leukemia, vol.26, pp.2538-2545, 2012. ,
Advances in the measurement of red blood cell deformability: A brief review, J. Cell. Biotechnol, vol.1, pp.63-79, 2015. ,
Four-color flow cytometric analysis of myeloma plasma cells, Am. J. Clin. Pathol, vol.126, pp.908-915, 2006. ,
,
A gene expression signature for high-risk multiple myeloma, Leukemia, vol.26, pp.2406-2413, 2012. ,
Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease, Blood, vol.114, pp.3413-3421, 2009. ,
Immunophenotyping in multiple myeloma and related plasma cell disorders, Best Pract. Res. Clin. Haematol, vol.23, pp.433-451, 2010. ,
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016. ,
,
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines, Mayo Clin. Proc, vol.84, pp.1095-1110, 2009. ,
,
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study, Leukemia, vol.26, pp.149-157, 2012. ,
Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin. Proc, vol.78, pp.21-33, 2003. ,
,
Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use, BMC Med. Genomics, vol.7, p.25, 2014. ,
,
Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission, PloS One, vol.7, p.42019, 2012. ,
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders, Leukemia, vol.28, pp.1299-1307, 2014. ,
, , 2000.
Down-regulation of Transcobalamin Receptor TCblR/CD320 by siRNA Inhibits Cobalamin uptake and Proliferation of Cells in, Culture. Exp. Cell Res, vol.317, pp.1603-1607, 2011. ,
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient, Cytometry B Clin. Cytom, vol.90, pp.14-20, 2016. ,
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.22, pp.5428-5433, 2016. ,
,
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium, Am. J. Hematol, vol.89, pp.1159-1160, 2014. ,
The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells, Eur. J. Immunol, vol.43, pp.2151-2161, 2013. ,
Novel secreted isoform of adhesion molecule ICAM-4: potential regulator of membrane-associated ICAM-4 interactions, Blood, vol.101, pp.1790-1797, 2003. ,
,
, Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells, Ann. Hematol, vol.64, pp.132-139
Chapter 2 -Reference ranges and normal values, pp.11-24, 2006. ,
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma, Am. J. Clin. Pathol, vol.121, pp.482-488, 2004. ,
Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study, Leuk. Lymphoma, vol.49, pp.306-314, 2008. ,
Automated gating of flow cytometry data via robust model-based clustering, Cytom. Part J. Int. Soc. Anal. Cytol, vol.73, pp.321-332, 2008. ,
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, p.91, 2014. ,
Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia, Mol. Cancer, vol.10, p.42, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00596532
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma, N. Engl. J. Med, vol.373, pp.1207-1219, 2015. ,
Recovery of functional human lymphocytes from Leukotrap filters, J. Immunol. Methods, vol.121, pp.33-38, 1989. ,
Non-secretory myeloma: a clinician's guide, Oncol. Williston Park N, vol.27, p.930, 2013. ,
,
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, N. Engl. J. Med, vol.373, pp.621-631, 2015. ,
The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells, Org. Biomol. Chem, vol.12, pp.8803-8822, 2014. ,
Data Analysis in Flow Cytometry: The Future Just Started, Cytom. Part J. Int. Soc. Anal. Cytol, vol.77, pp.705-713, 2010. ,
,
First-In-Human Phase I Dose Escalation Study of a, 2010. ,
, Patients with Advanced Stage B Cell Chronic Lymphocytic Leukemia (B-CLL) or Multiple Myeloma (MM)
Minimal residual disease in multiple myeloma: bringing the bench to the bedside, Nat. Rev. Clin. Oncol, vol.12, pp.286-295, 2015. ,
Hemolysis by surfactants -A review, Adv. Colloid Interface Sci, vol.228, pp.1-16, 2016. ,
Single tube, six-color flow cytometric analysis is a sensitive and cost-effective technique for assaying clonal plasma cells, Am. J. Clin. Pathol, vol.133, pp.694-699, 2010. ,
,
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study, Br. J. Haematol, vol.163, pp.581-589, 2013. ,
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014. ,
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma, Blood, vol.123, pp.3073-3079, 2014. ,
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality, Blood, vol.126, pp.858-862, 2015. ,
Expression and kinetics of cytokines determined by intracellular staining using flow cytometry, J. Immunol. Methods, vol.223, pp.115-121, 1999. ,
Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy, J. Clin. Oncol, vol.26, pp.2737-2744, 2008. ,
A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone), J. Clin, 2015. ,
, Oncol, vol.33
Leukocyte filtration in cardiac surgery: a review, Perfusion, vol.16, pp.361-370, 2001. ,
Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma, J. Clin. Immunol, vol.13, pp.41-48, 1993. ,
,
, Soluble CD16 in Plasma Cell Dyscrasias, Leuk. Lymphoma, vol.32, pp.467-474
,
, antibody combination and analysis strategy, Cytometry B Clin. Cytom
Filter Buffy Coats (FBC): a source of peripheral blood leukocytes recovered from leukocyte depletion filters, J. Immunol. Methods, vol.307, pp.150-166, 2005. ,
CD200 is a new prognostic factor in multiple myeloma, Blood, vol.108, pp.4194-4197, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130595
CD200: a putative therapeutic target in cancer, Biochem. Biophys. Res. Commun, vol.366, pp.117-122, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00195258
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-582, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00550232
,
Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors, Mol. Cancer Ther, vol.11, pp.2685-2692, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00760269
The genetic architecture of multiple myeloma, 2012. ,
, Nat. Rev. Cancer, vol.12, pp.335-348
Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders, Leukemia, vol.21, pp.2043-2046, 2007. ,
Leukocyte reduction in cardiovascular surgery, Perfusion, vol.16, pp.371-380, 2001. ,
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents, Cytometry B Clin. Cytom, vol.90, pp.81-90, 2016. ,
,
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib, Blood, vol.109, pp.3177-3188, 2007. ,
, , 1985.
,
, The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent for transducing signals to induce early B cell differentiation, Immunity, vol.7, pp.559-570
An approach for diagnosing plasma cell myeloma by threecolor flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells, Diagn. Pathol, vol.7, p.131, 2012. ,
The curvHDR method for gating flow cytometry samples, BMC Bioinformatics, vol.11, p.44, 2010. ,
CD138 (Syndecan-1), a Plasma Cell Marker, Am. J. Clin. Pathol, vol.121, pp.254-263, 2004. ,
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma, Am. J. Pathol, vol.152, pp.1655-1665, 1998. ,
Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma, Cytometry B Clin. Cytom, vol.90, pp.40-46, 2016. ,
CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma, Am. J. Clin. Pathol, vol.138, pp.867-876, 2012. ,
,
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential, Leukemia, vol.29, pp.1186-1194, 2015. ,
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation, Blood, vol.112, pp.4017-4023, 2008. ,
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Cytometry B Clin. Cytom, vol.78, pp.239-252, 2010. ,
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma, J. Clin. Oncol, vol.29, pp.1627-1633, 2011. ,
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma, Blood, vol.119, pp.687-691, 2012. ,
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials, Am. J. Pathol, vol.181, pp.1870-1878, 2012. ,
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile, Blood, vol.122, pp.3591-3598, 2013. ,
, , 2014.
New criteria for response assessment: role of minimal residual disease in multiple myeloma, Blood, vol.125, pp.3059-3068, 2015. ,
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma, Haematologica, vol.100, pp.53-55, 2015. ,
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients, Blood, vol.127, pp.3165-3174, 2016. ,
,
Differentiation stage of myeloma plasma cells: biological and clinical significance, Leukemia, vol.31, pp.382-392, 2017. ,
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol, vol.33, pp.2863-2869, 2015. ,
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.754-766, 2016. ,
A new "Logicle" display method avoids deceptive effects of logarithmic scaling for low signals and compensated data, Cytom. Part J. Int. Soc. Anal, 2006. ,
, Cytol, vol.69, pp.541-551
, , 2011.
, Cytometry B Clin. Cytom, vol.80, pp.318-323
Flow cytometric analysis of kinase signaling cascades, Methods Mol. Biol. Clifton NJ, vol.263, pp.67-94, 2004. ,
Update on Leucocyte Depletion of Blood Components by Filtration, Transfus. Sci, vol.19, pp.321-328, 1998. ,
Différenciation lymphocytaire B normale, Rev. Francoph. Lab, pp.27-35, 2013. ,
Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases, Cytometry B Clin. Cytom, vol.90, pp.91-100, 2016. ,
c-Myc: linking transformation and genomic instability, Curr. Mol. Med, vol.8, pp.446-458, 2008. ,
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry, Leukemia, vol.28, pp.391-397, 2014. ,
Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma, Eur. J. Haematol, vol.85, pp.416-423, 2010. ,
, , 2009.
, Proc. Natl. Acad. Sci. U. S. A, vol.106, pp.8519-8524
Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data, Cytometry B Clin. Cytom, 2010. ,
, Cellular Uptake of Cobalamin: Transcobalamin and the, 2013.
, Biochimie, vol.95, pp.1008-1018
Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells, J. Cancer Ther, vol.4, pp.1074-1081, 2013. ,
Multiple myeloma, Lancet, vol.374, pp.324-339, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130206
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders, Br. J. Haematol, vol.149, pp.334-351, 2010. ,
Evolving diagnostic criteria for multiple myeloma, Hematol. Am. Soc. Hematol. Educ. Program, pp.272-278, 2015. ,
,
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma, Blood, vol.106, pp.4050-4053, 2005. ,
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance, Blood, vol.106, pp.812-817, 2005. ,
, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, vol.117, pp.4691-4695, 2011.
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation, Blood, vol.100, pp.3095-3100, 2002. ,
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy, Haematologica, vol.91, pp.1577-1578, 2006. ,
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, Haematologica, vol.93, pp.431-438, 2008. ,
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.31, pp.2540-2547, 2013. ,
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction, Blood, vol.125, pp.1932-1935, 2015. ,
, , 2010.
, Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma, Int. J. Lab. Hematol, vol.32, pp.190-196
Band 3, the human red cell chloride/bicarbonate anion exchanger (AE1, SLC4A1), in a structural context, Biochim. Biophys. Acta, vol.1858, pp.1507-1532, 2016. ,
Modeling risk stratification in human cancer, Bioinforma. Oxf. Engl, vol.29, pp.1149-1157, 2013. ,
Modeling risk stratification in human cancer, Bioinformatics, vol.29, pp.1149-1157, 2013. ,
, , 2007.
, Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma, Br. J. Haematol, vol.138, pp.756-760
limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res, vol.43, p.47, 2015. ,
Phenotypic characterization of the human myeloma cell growth fraction, Blood, vol.105, pp.4845-4848, 2005. ,
A single-tube multiparameter seven, 2013. ,
A single-tube multiparameter seven, 2013. ,
, Immunophenotype of Normal and Myelomatous Plasma, vol.5, 2014.
IL-2 receptor alpha chain (CD25, TAC) expression defines a crucial stage in pre-B cell development, Int. Immunol, vol.6, pp.1257-1264, 1994. ,
,
CD38 expression in early B-cell precursors contributes to extracellular signalregulated kinase-mediated apoptosis, Immunology, vol.144, pp.271-281, 2015. ,
Utilisation de sources polychromes pour le diagnostic cytologique : application à l'hématologie (Limoges), 2011. ,
Fuzzy clustering with high contrast, J. Comput. Appl. Math, vol.64, pp.81-90, 1995. ,
TM4 microarray software suite, Methods Enzymol, vol.411, pp.134-193, 2006. ,
Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities, Leuk. Lymphoma, vol.56, pp.426-433, 2015. ,
A new staging system for multiple myeloma based on the number of S-phase plasma cells, Blood, vol.85, pp.448-455, 1995. ,
AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease, J. Leukoc. Biol, vol.98, pp.173-184, 2015. ,
Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry, Haematologica, vol.90, pp.1365-1372, 2005. ,
Using flowViz to visualize flow cytometry data, Bioinforma. Oxf. Engl, vol.24, pp.878-879, 2008. ,
Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science, vol.270, pp.467-470, 1995. ,
,
Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells, Haematologica, vol.98, pp.279-287, 2013. ,
,
Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells, Haematologica, vol.98, pp.279-287, 2013. ,
Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond, 2001. ,
Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects, Biochim. Biophys. Acta, vol.1508, pp.210-234, 2000. ,
Immunophenotypic Differentiation Between Neoplastic Plasma Cells in Mature B-Cell Lymphoma vs Plasma Cell Myeloma, Am. J. Clin. Pathol, vol.127, pp.176-181, 2007. ,
New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab, Ther. Clin. Risk Manag, vol.11, pp.1113-1122, 2015. ,
,
A validated gene expression model of highrisk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, Blood, vol.109, pp.2276-2284, 2007. ,
,
Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma, Blood Cancer J, vol.4, p.250, 2014. ,
Leukocyte depletion for safe blood transfusion, Biotechnol. J, vol.4, pp.1140-1151, 2009. ,
Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens, J. Clin. Invest, vol.94, pp.1043-1049, 1994. ,
Monoclonal antibodies in myeloma, Clin. Adv. Hematol. Oncol. HO, vol.13, pp.599-609, 2015. ,
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies, Blood, vol.98, pp.2837-2844, 2001. ,
The relationship between red blood cell deformability metrics and perfusion of an artificial microvascular network, 2014. ,
, Clin. Hemorheol. Microcirc, vol.57, pp.291-305
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation, Blood, vol.102, pp.1588-1594, 2003. ,
,
Regulation of multiple myeloma survival and progression by CD1d, Blood, vol.113, pp.2498-2507, 2009. ,
Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization, Mol. Biol. Cell, vol.9, pp.3273-3297, 1998. ,
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition, Cytometry B Clin. Cytom, vol.90, pp.26-30, 2016. ,
Genesis: cluster analysis of microarray data, Bioinforma. Oxf. Engl, vol.18, pp.207-208, 2002. ,
Misty Mountain clustering: application to fast unsupervised flow cytometry gating, BMC Bioinformatics, vol.11, p.502, 2010. ,
Tumorassociated macrophages as a prognostic parameter in multiple myeloma, Ann. Hematol, vol.92, p.669, 2013. ,
Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis, Pathol. Int, vol.59, pp.804-808, 2009. ,
Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data, The Oncologist, vol.18, pp.37-45, 2013. ,
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases, Leuk. Res, vol.38, pp.371-376, 2014. ,
Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry, Blood, vol.76, pp.1739-1747, 1990. ,
Automated hematology analysers and spurious counts, Ann. Biol. Clin, vol.68, pp.393-407, 2010. ,
, Translocations and Jumping Rearrangements at 8q24, 2016.
, Result in over-Expression of MYC and are Key Drivers of Disease Progression, Blood, vol.128, pp.115-115
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential, FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol, vol.21, pp.691-699, 2007. ,
Significance analysis of microarrays applied to the ionizing radiation response, Proc. Natl. Acad. Sci. U. S. A, vol.98, pp.5116-5121, 2001. ,
A singletube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma, Leukemia, vol.21, pp.2046-2049, 2007. ,
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen, Haematologica, vol.101, pp.69-71, 2016. ,
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects, Leukemia, vol.17, pp.1013-1034, 2003. ,
, An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation, vol.6, 2015.
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients, Clin. Lymphoma Myeloma Leuk, vol.14, pp.131-139, 2014. ,
Current and future applications of flow cytometry in aquatic microbiology, FEMS Microbiol. Rev, vol.24, pp.429-448, 2000. ,
Leucocyte depletion during cardiac surgery: a comparison of different filtration strategies, Perfusion, vol.18, pp.31-38, 2003. ,
Method for enriching adherent monocyte populations, 2006. ,
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.33, pp.3911-3920, 2015. ,
MArray: analysing single, replicated or reversed microarray experiments, Bioinforma. Oxf. Engl, vol.18, pp.1139-1140, 2002. ,
CD109 plays a role in osteoclastogenesis, PloS One, vol.8, 2013. ,
Comparison of five clustering algorithms to classify phytoplankton from flow cytometry data, Cytometry, vol.44, pp.210-217, 2001. ,
URL : https://hal.archives-ouvertes.fr/hal-01651729
Immunotherapy targeting inhibitory Fc? receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization, J. Immunol. Baltim. Md, pp.4130-4140, 2013. ,
Leucocyte Depletion Of The Blood Supply -How Will Patients Benefit?, Br. J. Haematol, vol.110, pp.256-272, 2000. ,
FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis, Nat. Immunol, vol.8, pp.419-429, 2007. ,
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM), Hematol. J. Off. J. Eur. Haematol. Assoc. EHA, vol.3, pp.185-192, 2002. ,
Composition of Normal Red Cell Membranes, In Cell Membrane, pp.27-46, 2003. ,
Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells, Cell. Mol. Immunol, vol.8, pp.157-163, 2011. ,
Whole blood leukocytes isolation with microfabricated filter for cell analysis, Cytom. Part J. Int. Soc. Anal. Cytol, vol.79, pp.1009-1015, 2011. ,
AIM, a murine apoptosis inhibitory factor, induces strong and sustained growth inhibition of B lymphocytes in combination with TGF-?1, Eur. J. Immunol, vol.29, pp.1086-1093, 1999. ,
Emerging antibodies for the treatment of multiple myeloma, Expert Opin. Emerg. Drugs, vol.21, pp.225-237, 2016. ,
Data reduction for spectral clustering to analyze high throughput flow cytometry data, BMC Bioinformatics, vol.11, p.403, 2010. ,
Intracellular cytokine detection by flow cytometry in pigs: Fixation, permeabilization and cell surface staining, J. Immunol. Methods, vol.327, pp.18-29, 2007. ,
The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2028, 2006. ,
Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells, Haematologica, vol.91, pp.920-928, 2006. ,
,
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy, Blood, vol.111, pp.3403-3406, 2008. ,
The molecular characterization and clinical management of multiple myeloma in the post-genome era, Leukemia, vol.23, 1941. ,